The published long-term data suggests that the treatment could maintain its dominant position in the CF market.

Patients were randomised 1:1 to receive Nucala 100mg or placebo subcutaneously every four weeks in addition to standard ...

Following completion of the dose escalation phase in relapsed/refractory acute leukemia patients with FLT3 mutations, Biomea ...

At ARVO 2025, in Salt Lake City, Utah, Viha Vig, talked about her poster presentation investigating the relationship between ocular and systemic mitochondrial diseases and dementia ...

Treatment practices in the U.S. show approximately 75% of diagnosed pulmonary sarcoidosis patients require treatment with ...

Wright Twp. supervisors and the township’s Environmental Advisory Committee honored winners of the EAC’s environmental poster ...

People who died by suicide frequently presented to hospitals within the previous year, indicating that these visits could be ...

Every successful nonprofit fundraising campaign revolves around visual storytelling. As messages are the order of the day in a digital world, an image combined with the right message can produce ...

PDS Biotechnology Corporation (NASDAQ: PDSB) Q1 2025 Earnings Call Transcript May 14, 2025 PDS Biotechnology Corporation ...

The 54th International Symposium on High Performance Liquid Phase Separations and Related Techniques (HPLC 2025) will be held ...

Four Hiram College students recently had the opportunity to showcase their original research at regional and statewide ...